Ireland
--:--IST
Recruiting Not applicable

Motor Slowing and Its Lesion-related Correlates in Alzheimer's Disease

NCT02811653 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2015-12-16
Last updated
2026-05-28

Condition(s) studied

Alzheimer Disease

Investigational drug(s) / intervention(s)

Brain MRIneuropsychological evaluationBlood →

Study summary

In AD (Alzheimer disease), the anatomic correlates of attention disorders (as evaluated by motor slowing) have not been thoroughly characterized.

Eligibility

Sex
ALL
Min age
40 Years
Max age
85 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Patients * Age between 40 and 85 * French mother tongue * Consulting at the Amiens Memory Resource and Research Centre (CMRR) for: * MCI, according to Albert et al.'s criteria (Albert et al., 2011) * Mild dementia (MMSE\>20) due to AD, according to McKhann's criteria (McKhann et al., 2011). * Mild dementia due to LBD, according to McKeith et al.'s criteria (McKeith et al., 2005). * Mild dementia due to FTLD, according to Rascovsky et al.'s criteria (Rascovsky et al., 2011). * Social security coverage * Healthy controls * Healthy age and gender matched volunteers will be recruited into the study from the general population. Exclusion Criteria: * Reading or writing difficulties related to a learning disorder or illiteracy. * A medical history with a potentially significant impact on cognition (non-corrected thyroid disorders or heart failure): * NYHA stage IV dyspnoea. * respiratory impairment requiring oxygen therapy. * liver impairment. * kidney failure, progressing neoplastic disease, or past or present alcohol abuse. * Past or present neurological disorders other than those having prompted consultation in the Memory Clinic: * stroke. * meningitis or encephalitis. * severe head injury. * sensorimotor impairments (sensory, proprioceptive, cerebellar and visual impairments). * epilepsy (requiring ongoing treatment), * psychiatric disorders (other than treated depression). * treatment with psychotropic medications (other than anxiolytics or antidepressant withdrawn or initiated in the previous month). Patients with parkinsonian syndrome were examined in the "on-drug" state. * Impossibility to perform a neuropsychological evaluation or brain MRI. * Withdrawal from the study at any time, if desired. * Pregnancy * Contra-indication to MRI: * nerve stimulators * cochlear implants * ferromagnetic foreign bodies close to nervous structures in the eye or brain * cerebral shunts * dental appliances * Legal guardianship or incarceration.

Primary outcome measure(s)

  • median SRT (simple reaction time) to a stimulus (in milliseconds) — Day 0

Trial sites (1)

FacilityCityRegionStatus
CHU Amiens Amiens France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02811653 on ClinicalTrials.gov ↗ ← All trials in France